Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common statin help kids with kidney disease and high cholesterol?

NCT ID NCT07497776

Disease control Sponsor: National Institute of Kidney Disease and Urology (NIKDU) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 4 trial tested the drug atorvastatin (Lipitor) in 100 children aged 8-18 with steroid-sensitive nephrotic syndrome and high cholesterol. The goal was to see if the drug safely lowers cholesterol to healthy levels within 3 to 6 months. The study compared atorvastatin to a placebo or standard care to measure effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atorvastatin (a statin drug, also known as Lipitor)
What this could lead to
If it works, this could provide a safe way to manage high cholesterol in children with nephrotic syndrome, reducing heart risks.
What could go wrong
This is a small, completed Phase 4 trial with only 100 children. Results may not apply to all patients, and statins can have side effects like muscle pain or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

100 people

The number who actually took part.

Started

Jan 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

8 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 8-18 years with known cases of steroid sensitive nephrotic syndrome * LDL ≥ 130 mg/dl in two consecutive serum fasting lipid profile, at least 4 weeks apart * while on remission * free of acute infection. Exclusion criteria * Children with previously diagnosed hyperlipidemia other than Nephrotic Syndrome. * Children with steroid resistant nephrotic syndrome * Children already on lipid lowering drugs * Secondary nephrotic syndrome. * Those parents/patients who refused to participate. 4\. Secondary nephrotic syndrome (SLE, amyloidosis etc.) 5. Nephrotic syndrome (initial episode). 6. Children taking Anti TB drug or anticonvulsant drugs. 7. Children having any active liver disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder nephrotic syndrome nephrotic syndrome of childhood - steroid sensitive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidaemia

Contacts and locations

Locations

  • National Institute of kidney diseases and Urology

    Dhaka, Dhaka Division, 1207, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.